Similarly to EGPA, biologics targeting IL5/IL5r have shown to improve exacerbation frequency and OCS consumption in patient with SEA and bronchiectasis (30). This evidence concerns the gene IL5RA and eosinophilic granulomatosis with polyangiitis.